NVO Novo Nordisk A/S Common Stock
$44.69
Price · May 22, 2026
52W Range
$35–$81
21% of range
Analyst Rating
HOLD
37 analysts
Price Target
$47
+4% upside
P/E (TTM)
—
ROE
—
Net Profit Margin
—
NVO Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range
Price
$44.69
Market Cap
—
P/E (TTM)
—
EPS (TTM)
—
Revenue (TTM)
—
Div Yield
—
ROE
—
Debt/Equity
—
52W Range
$35 – $81
NVO Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view
Configure
10-Year Performance Revenue, net income, margins and EPS trends
Revenue & Net Income
—
EPS
—
Free Cash Flow
—
Margins
—
Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?
Metric
5Y trend
NVO
Peer Median
Profitability Gross, operating and net margins; ROE, ROA, ROIC
Metric
5Y trend
NVO
Peer Median
Financial Health Debt, liquidity, solvency — balance sheet strength
Metric
5Y trend
NVO
Peer Median
Growth Revenue, EPS and net income growth: YoY, 3Y CAGR, 5Y CAGR
Metric
5Y trend
NVO
Peer Median
Capital Efficiency Asset turnover, inventory turnover, receivables turnover
Metric
5Y trend
NVO
Peer Median
Dividends Yield, payout ratio, dividend history, 5Y CAGR
Dividend Yield
—
Payout Ratio
—
5Y Div CAGR
—
| Ex-date | Amount |
|---|---|
| March 30, 2026 | $1.2750 |
| Aug. 18, 2025 | $0.5840 |
| March 31, 2025 | $1.0990 |
| Aug. 16, 2024 | $0.5130 |
| March 22, 2024 | $0.9300 |
| Aug. 18, 2023 | $0.4420 |
| March 24, 2023 | $0.5945 |
| Aug. 12, 2022 | $0.2920 |
| March 25, 2022 | $0.5180 |
| Aug. 16, 2021 | $0.2785 |
| March 26, 2021 | $0.4745 |
| Aug. 14, 2020 | $0.2590 |
| March 27, 2020 | $0.3935 |
| Aug. 16, 2019 | $0.2245 |
| March 22, 2019 | $0.3945 |
| Aug. 17, 2018 | $0.2335 |
| March 23, 2018 | $0.3350 |
| Aug. 17, 2017 | $0.2370 |
| March 23, 2017 | $0.3315 |
| Aug. 11, 2016 | $0.2235 |
NVO Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside
HOLD
37 analysts
- Strong Buy 5 13.5%
- Buy 7 18.9%
- Hold 23 62.2%
- Sell 1 2.7%
- Strong Sell 1 2.7%
12-Month Price Target
12 analysts · 2026-05-20
Median
$44.49
Mean
$46.68
Now
$44.69
Low
$39.53
High
$64.13
Median target
$44.49
-0.4%
Mean target
$46.68
+4.4%
Earnings History EPS actual vs estimate, surprise %, beat rate, next earnings date
Avg Surprise
0.23%
| Period | EPS Actual | EPS Est | Surprise |
|---|---|---|---|
| March 31, 2026 | $6.63 | $5.39 | 1.2% |
| Dec. 31, 2025 | $6.04 | $5.96 | 0.08% |
| Sept. 30, 2025 | $4.50 | $4.84 | -0.34% |
| June 30, 2025 | $5.96 | $6.03 | -0.07% |
| March 31, 2025 | $6.53 | $6.28 | 0.25% |
Latest News Recent headlines mentioning this company
- 3 Deeply Undervalued Stocks You Can Buy for Less Than $100 Right Now
- Novo Nordisk says high-dose Wegovy helped some patients lose nearly 28% of their weight
- Is This News From Novo Nordisk a Warning for Eli Lilly Shareholders?
- Healthy Returns: First Ozempic generics in Canada will be a test case for Novo Nordisk
- Novo Nordisk Swallows the Competition with Wegovy Pill Surge
- Wegovy pill sales smash forecasts after launch as Novo Nordisk hikes guidance
- Eli Lilly’s (LLY) Weight Loss Pill is Better Than Novo’s, Says Jim Cramer
- Lilly's obesity pill records modest second week as battle with Novo intensifies
- A Monthly Weight Loss Shot? Why Pfizer Could Topple Lilly's and Novo's GLP-1 Duopoly
- The $1 Trillion Race: Why Eli Lilly Is Leaving Novo Nordisk in the Dust
My Metrics Your personal watchlist — selected rows from Full Fundamentals
📊
Pick the metrics that matter to you — click the ➕ next to any row in Full Fundamentals above.
Your selection is saved and follows you across all tickers.